AOD9604 (also known as Frag 176-191) is an HGH fragment focused on lipolytic effects specifically, with no effect on growth or insulin resistance. Secondary and tertiary studies are ongoing supporting its use for osteoarthritis, hypercholesterolemia, bone and cartilage repair, and pain (not surprisingly, all HGH associated benefits).

The safety profile of AOD9604 presents a potential interest for those using more aggressive weight-loss peptide regimens (semaglutide and tirzepatide) by allowing for a lower clinically effective dose of these aggressive peptides to be required, and creating a more lipolytic-focused effort rather than a catabolic side effect profile.